Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: Herc who wrote (350)	7/22/1999 9:16:00 AM
From: JZGalt	Respond to of 399

I am saying that ARQL could be an embryonic SEPR. And I could be Bill Gates.

To: Herc who wrote (350)	7/22/1999 9:42:00 AM
From: rkrw	Read Replies (1) \| Respond to of 399

Herc, The Pfizer deal is non-royalty bearing. That's very non-Sepracor like.

To: Herc who wrote (350)	7/22/1999 10:27:00 AM
From: tommysdad	Read Replies (1) \| Respond to of 399

<<ARQL and SEPR both design molecules for the drug industry. What other companies fulfill that niche?>> NOT true. SEPR takes KNOWN drugs and either (a) develops a KNOWN active metabolite or (b) separates the enantiomers and develops the eutomer (if you don't know what those terms mean, you may as well compare SEPR to ZZZBest). ARQL makes libraries of new molecules for other companies to test. <<What other companies fulfill that niche?>> Oh, PCOP, CCHM, Trega among public companies; at least half a dozen private companies.